AVIR vs. NKTX, VTYX, VRCA, KMDA, SBTX, ORGO, ATAI, PGEN, CRMD, and NLTX
Should you be buying Atea Pharmaceuticals stock or one of its competitors? The main competitors of Atea Pharmaceuticals include Nkarta (NKTX), Ventyx Biosciences (VTYX), Verrica Pharmaceuticals (VRCA), Kamada (KMDA), Silverback Therapeutics (SBTX), Organogenesis (ORGO), Atai Life Sciences (ATAI), Precigen (PGEN), CorMedix (CRMD), and Neoleukin Therapeutics (NLTX). These companies are all part of the "pharmaceutical preparations" industry.
Atea Pharmaceuticals (NASDAQ:AVIR) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.
Nkarta has lower revenue, but higher earnings than Atea Pharmaceuticals. Nkarta is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Atea Pharmaceuticals has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500. Comparatively, Nkarta has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500.
86.7% of Atea Pharmaceuticals shares are held by institutional investors. Comparatively, 80.5% of Nkarta shares are held by institutional investors. 14.5% of Atea Pharmaceuticals shares are held by company insiders. Comparatively, 5.6% of Nkarta shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Nkarta had 13 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 17 mentions for Nkarta and 4 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.13 beat Nkarta's score of 0.06 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.
Atea Pharmaceuticals' return on equity of -23.07% beat Nkarta's return on equity.
Nkarta has a consensus target price of $17.83, indicating a potential upside of 171.02%. Given Nkarta's stronger consensus rating and higher probable upside, analysts clearly believe Nkarta is more favorable than Atea Pharmaceuticals.
Nkarta received 31 more outperform votes than Atea Pharmaceuticals when rated by MarketBeat users. Likewise, 72.73% of users gave Nkarta an outperform vote while only 47.22% of users gave Atea Pharmaceuticals an outperform vote.
Summary
Atea Pharmaceuticals and Nkarta tied by winning 8 of the 16 factors compared between the two stocks.
Get Atea Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Atea Pharmaceuticals Competitors List
Related Companies and Tools
